NASDAQ:PRLD Prelude Therapeutics Q2 2025 Earnings Report $4.66 +0.07 (+1.53%) As of 12:08 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Prelude Therapeutics EPS ResultsActual EPS-$0.41Consensus EPS -$0.45Beat/MissBeat by +$0.04One Year Ago EPSN/APrelude Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/APrelude Therapeutics Announcement DetailsQuarterQ2 2025Date8/14/2025TimeBefore Market OpensConference Call DateThursday, August 14, 2025Conference Call Time7:00AM ETUpcoming EarningsPrelude Therapeutics' Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Prelude Therapeutics Earnings HeadlinesPrelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 11 at 7:01 AM | globenewswire.comPrelude Therapeutics Incorporated (NASDAQ:PRLD) Receives Average Recommendation of "Hold" from AnalystsSeptember 11 at 3:17 AM | americanbankingnews.comEvery Major Market Reset Had These 3 Warning Signs First. All 3 Are Flashing Right Now.U.S. debt is closing in on 38 trillion as foreign buyers pull back, tightening liquidity across markets. The 2026 Munich Security Report just called the global order Under Destruction, citing trade fragmentation and weakened institutions. Meanwhile, central banks are buying gold at record levels without explanation, and gold has outpaced the S&P 500 in 2026.September 14 at 1:00 AM | Golden Crest Metals (Ad)Prelude Therapeutics, Incorporated: Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A ...September 10, 2026 | finanznachrichten.dePrelude Therapeutics Receives FDA Clearance For PRT13722 IND In HR+/HER2-Breast CancerSeptember 10, 2026 | rttnews.comPrelude Therapeutics Cleared by FDA for Phase 1 Breast Cancer Drug TrialSeptember 10, 2026 | finance.yahoo.comSee More Prelude Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Prelude Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Prelude Therapeutics and other key companies, straight to your email. Email Address About Prelude TherapeuticsPrelude Therapeutics (NASDAQ:PRLD) Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines for cancer. The company’s research is centered on small-molecule therapies designed to target biological mechanisms that cancer cells depend on, including epigenetic regulators and other proteins involved in tumor growth and survival. Prelude’s development programs have included PRT2527, a selective cyclin-dependent kinase 9 (CDK9) inhibitor; PRT3789, a SMARCA2 protein degrader; and PRT1419, an inhibitor of the MCL1 protein. These candidates have been investigated for potential use in treating cancers with specific molecular characteristics, including hematologic malignancies and solid tumors. Founded in 2016 and headquartered in Wilmington, Delaware, Prelude has advanced its programs through preclinical research and clinical development in the United States. As a biotechnology company, its activities are primarily focused on research, drug development, and the evaluation of investigational therapies rather than commercial product sales.View Prelude Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/07 - 09/11Kroger’s Textbook Entry for Buy-and-Hold InvestorsOracle’s AI Spending Is Still Huge, But the Payoff Is Starting to Show in EarningsPlanet Labs Has Fallen Back to Earth, But Wall Street Still Sees a ReboundFabrinet, Dycom and Qualcomm: 3 AI Fallen Angels Wall Street Just Marked DownAmgen Drops 10% on a Trial It Didn't Even RunWhat Might it Take for D-Wave to Reset Its Course? Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
